Vastcon Inc.
$45,555.00 CAD
≈ 7 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- May 1, 2018 – March 31, 2019
- Reference
- nrc-cnrc:172-2018-2019-Q1-906588
Published purpose
Estrogen Receptor (ER) Positive breast cancer is the most common type and can be effectively treated with endocrine therapy. However, the major challenge is the endocrine therapy resistance and breast cancer recurrence in 50% of the patients. VastCo is developing a novel predictive test that could be combined with the receptor status test for the prediction of treatment response to endocrine therapy. This test would help Clinical Oncologists to design treatment regimen for better clinical outcome.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 3, 2026 from open.canada.ca Grants & Contributions